Maskan Bermudez Narges, Elman Scott A, Kirsner Robert S, Lev-Tov Hadar
Dr Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Ave RMSB 2023A, Miami, FL, USA.
Arch Dermatol Res. 2025 Jan 8;317(1):202. doi: 10.1007/s00403-024-03622-9.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects the axilla, inframammary folds, buttocks, inner thighs, and anogenital regions. Patients with moderate to severe HS often seek care in the emergency department and may require hospitalization; however, the lack of clear admission criteria and management guidelines presents significant challenges. To address these issues, we conducted a clinical review aimed at hospitalists and consulting dermatologists considering hospital admission for patients experiencing severe HS flares. Admission offers a unique opportunity to optimize care through specialized consultations, pain management, rescue therapy, and surgical planning. Furthermore, multimodal treatments, particularly biologics, are needed to achieve clinical remission in severe disease. Streamlining care during hospitalization for the early initiation of these therapies can significantly improve flare management and overall clinical outcomes for HS patients. This review aims to improve care for HS by providing clear and comprehensive guidance on its management in the inpatient setting.
化脓性汗腺炎（HS）是一种慢性炎症性疾病，影响腋窝、乳房下皱襞、臀部、大腿内侧和肛门生殖器区域。中重度HS患者常到急诊科就诊，可能需要住院治疗；然而，缺乏明确的入院标准和管理指南带来了重大挑战。为解决这些问题，我们针对考虑收治严重HS发作患者入院的住院医师和会诊皮肤科医生进行了一项临床综述。入院提供了一个独特的机会，可通过专科会诊、疼痛管理、抢救治疗和手术规划来优化护理。此外，严重疾病需要多模式治疗，尤其是生物制剂，以实现临床缓解。在住院期间简化护理流程以便尽早开始这些治疗，可显著改善HS患者的发作管理和总体临床结局。本综述旨在通过提供关于其住院管理的清晰全面指导，改善对HS的护理。
